129 results
Page 2 of 7
6-K
EX-99.2
q5cz znieraic5c
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.1
w3cetoygele
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.2
wv5wsr
4 Aug 22
Current report (foreign)
11:41am
6-K
EX-99.1
6lzg7puzk 8k60w
28 Jul 22
Current report (foreign)
2:52pm
6-K
EX-99
np95is vkumzh8ib
26 Jul 22
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
1:45pm
6-K
EX-99.1
uyygip29zlt 3no3gv9e
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
qrm4hq53u 2vcrwzr0
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
3jkdmj73tzph1xbe1vgv
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.3
lcr2m
10 May 22
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
4:34pm
6-K
EX-99.1
jbigwym89qaknzqae
29 Mar 22
RepliCel Announces Non-brokered Private Placement
1:02pm
6-K
EX-99.1
cn3 5419bfun786u
29 Mar 22
RepliCel Announces Material Patent Milestones
12:51pm
6-K
EX-99.2
f6vmr4po6vt0c kr
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
mmoqimz4piyoc7p
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
6-K
EX-99.1
5q5zp7 3f
2 Nov 21
RepliCel Announces Dermal Injector Update
12:31pm
6-K
EX-99.1
o83rky
14 Oct 21
51-102F3 Material Change Report
4:00pm
6-K
EX-99.1
94foja 3jtma7birc
13 Oct 21
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
12:00am
6-K
EX-99.2
0wt zr1r0
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
ilneirrkf2o an8q2
18 Aug 21
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
12:38pm
6-K
EX-99.1
37ob zkwbm2e66w8xy6
18 Aug 21
Current report (foreign)
12:20pm